Indication:
Drug Name- Nesina
Active Ingredient - Alogliptin
Alogliptin
Indication-
To improve blood sugar control in adults with type II diabetes
Approved by FDA on 25-01--2013 (Ref- FDA approved List- 2013)
Alogliptin Tablet 6.25mg/12.5mg/25mg
Indication-
To improve glycemic control in combination with other glucose lowering
medicinal products including insulin when these together with diet and
excercise, do not provide adequated glycemic control or as monotherapy
as adjunct to diet and excerise to improve glycemic control in adults
aged 18 years or older with typre 2 Diabetic mellitus
Approved by FDA on 27-08--2014 (Ref- FDA approved List- 2014)
Approved by (DCI) Drug Controller GENERAL - India For Marketing
( Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Alogliptin tablet 6.25mg/12.5mg/25mg 27-06-2014
To improve glycemic control in combination with other glucose
lowering medicinal products including insulin when these together
with diet and excercise do no provide adequate glycemic control
or as monotherapy as adjunct to diet and excercise to improve
glycemic control in adults 18 years with type 2 diabetes mellitus
Dosages/ Overdosage Etc:
Indication-
To improve glycemic control in combination with other glucose lowering
medicinal products including insulin when these together with diet and
excercise, do not provide adequated glycemic control or as monotherapy
as adjunct to diet and excerise to improve glycemic control in adults
aged 18 years or older with typre 2 Diabetic mellitus